ETRI’s Digital Twin System Proves Wearable Robots in Software First

South Korea’s Electronics and Telecommunications Research Institute (ETRI), a government-funded research body established in 1976, has developed a digital human-device twin system capable of verifying a wearable robot’s performance and user experience entirely in software, without requiring any patient to physically wear the device. The institute validated the system through joint experiments with the Glocal Clinical Trial Center at Pusan National University Hospital, comparing simulated outputs against real clinical evaluations in which patients performed rehabilitation and muscle-strengthening tasks while wearing exoskeletons.

The validation returned a correlation coefficient of 0.6 or higher between simulation results and clinical outcomes, a threshold the institute describes as comparable to the reliability of traditional patient-worn evaluations. For the wearable robotics sector, where every design iteration currently runs through hospital ethics boards and patient recruitment pipelines, the shift from physical wear tests to software-verified development cycles carries consequences well beyond any single lab announcement.

How the Old Method Broke Down

Building a wearable robot, the class of powered exoskeletons and assistive devices used in rehabilitation, walking assistance, and industrial muscle augmentation, has always demanded bodies. Clinical teams recruit patients, fit them with a prototype, log every sensor output, identify failure modes, send the device back to engineering, and start again. For neurological and musculoskeletal conditions, where the patient population is often medically fragile and geographically dispersed, assembling those cohorts is slow and expensive.

Researchers at Nanyang Technological University noted in a 2024 study on personalized digital twin simulation for assistive robots that one of the primary challenges in this field is “the time required for human trials, due to the need for approval from the Institutional Review Board and time for recruiting patients,” with cost and patient availability compounding each delay. A device that fails in the third iteration of wear tests can set a development program back by a year or more.

The institute’s framework does not eliminate clinical testing; final patient validation remains a requirement in any regulatory development pipeline. What it targets is the expensive early iteration phase that currently consumes the bulk of a program’s timeline. ETRI built an integrated software environment combining a physics-based model of the device with a personalized model of the user’s body, running thousands of simulated conditions before any hardware leaves the workshop. When the first human trial arrives, it is a confirmation of pre-optimized specifications rather than a discovery run into unknown failure modes.

Four Technologies Inside the ETRI Framework

The system rests on four distinct technical layers, each addressing a different dimension of what made earlier simulation approaches unreliable for this application. Beyond mechanical performance, the framework targets user experience (UX), the measurable quality of how a patient feels and interacts with a device during clinical use. The research was funded by South Korea’s Ministry of Science and ICT through the Institute of Information and Communications Technology Planning and Evaluation (IITP), the ministry’s principal R&D funding arm for applied ICT projects.

Building the Human Twin

The first layer addresses the most variable element in any wearable test: the person. The research team built the neuro-musculoskeletal digital human twin by quantitatively modeling the physical and cognitive characteristics specific to patients with neurological and musculoskeletal conditions. These are not generic body models borrowed from ergonomics databases. Each twin reflects the clinical profile of a specific target group, from stroke patients with impaired motor control to individuals requiring lower-limb musculoskeletal support, so engineers can stress-test a device configuration against dozens of simulated patient types before recruiting a single volunteer.

A control algorithm optimized for a 70-kilogram patient with partial leg paralysis may produce unsafe torque loads on a smaller-framed patient with a different neurological profile. Running those edge cases in software, rather than discovering them during a wear session, is where most of the time savings accumulate. The personalization layer makes that stress-testing computationally tractable rather than clinically dependent.

Linking Human to Device in Simulation

The third layer is where the engineering payoff becomes concrete. The simulation engine runs the interaction between the human twin and the device twin simultaneously, measuring how the exoskeleton transfers force through the body, how sensors respond to movement variation across different patient profiles, and whether the control algorithm stays responsive throughout. Outputs including wearability, usability, and interactivity had previously been assessed only through patient surveys and clinical observation. The framework converts them into numeric indicators that feed directly back into the device’s design file.

Converting that qualitative observation into a trackable numeric score is one of the system’s most practically significant contributions. When a rehabilitation clinician says a device feels awkward on certain patients, engineers currently lack a computational handle on the problem. A wearability score derived from thousands of simulated wear sessions gives them one, and one that does not require a human participant each time the parameter is adjusted.

An Evaluation Loop That Closes in Software

The fourth layer closes the development loop. The integrated evaluation system takes the numeric outputs from simulation and makes them immediately actionable: an engineer who adjusts a control parameter can see the predicted effect on wearability scores without scheduling a new wear session or waiting for ethics board approval of a protocol amendment. That design-simulate-evaluate cycle compresses from weeks to hours.

Yoon Daesub, director of ETRI’s AI Robot UX Research Section, said the team plans to expand the technology to “rehabilitation robots, walking assist devices, and industrial wearable robots,” signaling that the framework was built from the start as a platform for multiple device categories rather than a specialized tool for a single exoskeleton program. A 2026 patent filing listed by PatSnap confirms the institute is also developing AI model-based exoskeleton performance prediction using sensor data from deployed wearable devices, suggesting commercialization planning is already underway alongside the research publication.

Pusan National University Puts Numbers to the Test

ETRI validated the system through joint experiments at the Glocal Clinical Trial Center of Pusan National University Hospital, comparing simulated performance data against results from actual patients wearing wearable robots and performing five types of basic functional tests, spanning muscle strengthening exercises and rehabilitation therapy sessions. The institute reports that simulation and clinical outcomes aligned at a correlation threshold it describes as comparable to traditional patient-worn evaluations.

• 0.6+ validated correlation coefficient between digital twin simulation outputs and the clinical patient data collected during joint experiments at the Glocal Clinical Trial Center
• 5 types of basic functional tests used in clinical validation, spanning muscle strengthening and rehabilitation therapy tasks
• 4 distinct core technology layers secured across the full research program
• 1976 year the institute was founded as South Korea’s primary government-funded electronics and communications research body, operating under a mandate to develop world-first technologies in applied ICT

Achieving that level of alignment on a first published external validation is significant. Many computational biomechanics frameworks produce strong results on internal data sets but fail to sustain the comparison against an independent clinical cohort. Professor Park Jonghwan, of the Department of Convergence Medicine at Pusan National University Hospital, described the work as technology “expected to draw attention as essential software technology not only for wearable robots but also for the development of various other robots in the future.”

From Hospital Beds to Simulation Servers

The second-order shift here is in where most of the technical iteration in wearable robot development actually occurs. In the old pipeline, the clinical trial was a discovery mechanism: researchers often could not identify which configuration parameters were wrong until a patient wearing the device provided that feedback directly. The cost of that discovery sat inside the healthcare system, in hospital scheduling time, ethics board approval cycles, and the coordination load on rehabilitation staff managing multiple prototype iterations.

Kim Woojin, principal researcher in the institute’s AI Robot User Experience Research Section, summarized the operational change directly:

Previously, wear tests with actual users were essential for verifying the performance of wearable devices. Using the digital twin-based technology developed this time, diverse user characteristics can be virtually combined and verified, making it possible to derive optimal device specifications and control algorithms in advance with only minimal clinical trials.

The phrase “only minimal clinical trials” is the operational crux. Patient testing is not removed from the pipeline; the Pusan correlation result confirmed the simulation tracks real outcomes with sufficient reliability to trust. But the number of patient-wear iterations required at each design stage drops substantially, and that changes the economics of wearable robotics development for companies that currently cannot absorb three or four rounds of clinical testing per design iteration. For hospital ethics boards, the reduced iteration burden frees patient cohorts from cycling through multiple early-phase hardware variants that could have been refined in software first. The research team plans to transfer the technology to wearable robot manufacturers and specialized robotics companies, with follow-up R&D projects intended to raise completeness before commercial deployment.

A Market Waiting on Better Dev Tools

The timing aligns with a sector under mounting commercial pressure to shorten development cycles. According to the wearable robots and exoskeletons market forecast through 2031 compiled by Mordor Intelligence, the global market is projected to grow from $6.83 billion this year to $24.28 billion by 2031, at a compound annual growth rate of approximately 29 percent. Asia-Pacific is expected to be the fastest-growing region at 32.1 percent annually, driven by South Korean, Japanese, and Chinese government and corporate initiatives.

At that pace, the development bottleneck ETRI’s system addresses shifts from a research inconvenience to a commercial constraint. The parties with the most direct stake in faster, lower-cost wearable device validation span several categories:

• Wearable robot manufacturers in South Korea and Japan, facing growing competitive pressure as industrial and healthcare exoskeletons approach commercial-scale deployment; Hyundai’s X-ble Shoulder received national KS quality certification from the Korea Institute for Robot Industry Advancement (KIRIA) in March 2026, the first wearable robot to reach that standard nationally
• Hospital rehabilitation programs, which currently carry much of the subject-recruitment burden for iterative clinical trials and could redirect that capacity toward outcome-focused research once early-phase iteration moves to software
• Defense and industrial procurement programs, where agencies across the United States, South Korea, and Israel collectively allocated more than $620 million toward exoskeleton and wearable robotics procurement between 2023 and 2025
• Early-stage exoskeleton companies entering new markets, including Cyberdyne, which expanded into the U.S. rehabilitation network through a strategic agreement in early 2026, and Ekso Bionics, which began integrating NVIDIA computing capabilities into its device development pipeline in mid-2025
• Insurance and reimbursement bodies in Japan and Europe, where long-term care programs have begun covering assistive robot use and where validated simulation data could support faster coverage decisions for new device classes

The Regulatory Path Ahead

The one variable the framework cannot yet resolve on its own is the regulatory question. A validated correlation of 0.6 is a strong first result, but converting a correlation figure into an accepted regulatory evidence package requires navigating standards that are still being written, by agencies moving at different speeds toward the same destination.

Published in late 2024 through a collaboration between the U.S. Food and Drug Administration and Dassault Systèmes, the FDA-backed ENRICHMENT in silico clinical trial guide is a peer-reviewed 44-page document focused on “establishing credibility” in trials where computer models simulate patient populations. The ENRICHMENT Playbook is listed in the FDA’s Regulatory Science Tools Catalog, the agency’s official repository for peer-reviewed development resources. The European Medicines Agency has moved further still, establishing a formal review pathway for software modeling tools with associated user fees; the FDA currently lacks an equivalent funding structure for that review type.

ETRI’s physics-based device twin, grounded in the dynamics and control algorithms of the actual hardware rather than purely statistical inference, fits the technical credibility profile both agencies are gravitating toward. A purely statistical simulation would face credibility questions from regulators who want to audit the physics; a model built from validated control algorithms and sensor characteristics gives them something checkable. If follow-up work expands the validated patient profile coverage and pushes the correlation threshold higher across a broader range of device categories, the simulation pipeline could plausibly satisfy early-phase regulatory evidence requirements beyond rehabilitation exoskeletons. If the current result holds only at 0.6 against a narrow clinical cohort, the framework remains a powerful development accelerator but falls short of a partial substitute for clinical trials. The planned technology transfer to manufacturers will be the first real test of which path it takes.